Cargando…
Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
The EGFR gene is one of the most frequently mutated and/or amplified gene both in lung adenocarcinomas (LUAD) and in glioblastomas (GBMs). Although both tumor types depend on the mutation for growth, clinical benefit of EGFR tyrosine kinase inhibitors (TKIs) has only been observed in LUAD patients a...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316468/ https://www.ncbi.nlm.nih.gov/pubmed/30518123 http://dx.doi.org/10.3390/cancers10120489 |